Rezolute
RZLTRezolute, Inc. is a late-stage biotechnology company dedicated to developing novel therapies for rare diseases characterized by chronic hypoglycemia.
$475.68M-9.0%
Table of contents
Earnings
Next report
Sep 16, 2026 (in 2 months)EPS estimate-$0.13
Competitors
Profile
Rezolute, Inc. is a late-stage biotechnology company dedicated to developing novel therapies for rare diseases characterized by chronic hypoglycemia. The company's primary focus is on hyperinsulinism, utilizing a lead clinical asset that acts as an allosteric modulator of the insulin receptor to restore glucose balance.
Competitive position
Rezolute is a late-stage clinical player with multiple orphan and breakthrough designations for its lead asset in ultra-rare indications with no FDA-approved therapies.
GeographiesUnited States, European Union, United Kingdom
Customer segmentsRare disease patients, Specialized medical centers
Business modelR&D intensive, IP licensing
SuppliersContract manufacturing organizations, Contract research organizations, Raw material suppliers, IP licensors
CustomersSpecialty pharmacies, Hospitals, Rare disease patients
CountryUnited States of America
Listed2011
Employees51.0
CEONevan Charles Elam
SectorHealthcare
IndustryBiotechnology
Websiterezolutebio.com
FilingsSEC EDGAR
Questions, answered.
- What is Rezolute's market cap?
- Rezolute (RZLT) has a market capitalization of $475.7M and trades on NASDAQ.
- Who are Rezolute's competitors?
- Rezolute's key competitors include Amylyx Pharmaceuticals, Oric Pharmaceuticals, Inc. Common Stock, ALX Oncology Holdings Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Rezolute partner with?
- Rezolute's notable partners include XOMA Corporation, ActiveSite Pharmaceuticals, Handok, Inc..
- Where is Rezolute headquartered?
- Rezolute is headquartered in United States of America and employs approximately 51 people. It has been publicly traded since 2011.